Key takeaways:

Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of immunoglobulin replacement.

Serious infections occurred more in patients on therapy than those who stopped.

Perspective from Susan Ehrenkranz de Wolf, MD

Use of immunoglobulin replacement therapy has risen for patients with chronic lymphocytic leukemia during the previous 2 decades, but the treatment may not be preventing serious infections.

Results of a retrospective analysis showed immunoglobulin replacement therapy increased fourfold from 2008 to 2022, yet the rate of serious infections doubled during that time.

Data derived from Carrillo de Albornoz S, et al. Blood Adv. 2025;doi:10.1182/bloodadvances.2025015867.

“This is the first large, real-world study to foll

See Full Page